Psychiatriccenters.com

PSYCHIATRIC CENTERS AT SAN DIEGO
CURRICULUM VITAE
Grant G. Miller
PCSD~Feighner Research
PCSD~Feighner Research
6153 Fairmount Ave., # 140
1550 Hotel Circle North #270
San Diego, CA 92120
San Diego, CA 92108
(619) 528-4621
(619) 692-1003

EDUCATION AND TRAINING:


University of California, San Diego
Muir College Bachelors of Science – Psychology, 2005
PROFESSIONAL EXPERIENCE:

CLINICAL TRIAL EXPERIENCE
An International, Multi-centre, Double-blind, Randomized, Parallel-group, Placebo-controlled, Phase III study of the Efficacy and Safety of Quentiapine Fumerate (Seroquel, single oral 300 mg ore 600 mg dose) and Paroxetine as Monotherapy in Adult Patients with Bipolar Depression for 8 Weeks and Quentiapine in Continuation Treatment for 25 up to 52 weeks. A Phase II, Randomized, Double-Blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Two Flexible Dosing Regimens of MN-305 in Patients with DSM-IV Defined Generalized Anxiety Disorder (GAD). Protocol ARI-002, Single-Center, Open-Label, Fixed Dose Evaluation of the Efficacy, Change in Depression, Weight and Blood Chemistry of Lamictal in the Treatment of Bipolar In Adults. An Eight-Week, Double-Blind Placebo Controlled, Multicenter Study With Escitalopram-(10mg-qd) As Positive Control, Evaluating the Efficacy, Safety, Tolerability of a Fixed Dose of SR58611A (350 mg q12) In Outpatients With Major Depressive Disorder (MDD). An Eight-Week, Double-Blind, Placebo-Controlled, Multicenter Study With Escitalopram (10mg qd) As Positive Control, Evaluating The Efficacy, Safety, Tolerability of a Fixed Dose of SR58611A (350 mg q12) In Outpatients With Generalized Anxiety Disorder. A 10 week, Randomized, Double-Blind, Placebo-controlled, Parallell-Group, Flexible-Dosage Study to Evaluate the Efficacy and Safety of GABITRIL (up to 16 mg/day) in the Treatment of Adults with Generalized Anxiety Disorder. A 10-Week, Randomized, Double-Blind, Placebo-Controlled, Parallell-Group, Flexible-Dose, Study to Evaluate the Efficacy and Safety of GABITRIL (up to 16 mg/day) in the Treatment of Adults with Generalized Anxiety Disorder. A 12-Month, Open-Label, Flexible Dosage Study to Evaluate the Safety and Efficacy of GABITRIL Treatment (up to 16mg/day) in Adults With Generalized Anxiety Disorder. A Phase II, Randomized, Double-Blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Two Flexible Dosing Regimens of MN-305 in Patients with DSM-IV Defined Generalized Anxiety Disorder (GAD). “The Efficacy of Eszopiclone 3 mg as Adjunctive therapy in Subjects with Insomnia Related to Generalized anxiety Disorder (GAD)”. "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety and Tolerability of XBD173 in Patients with Generalized Anxiety Disorder". A Multicenter, Open-Label, Flexible-Dose, Parallel-Group Evaluation of the Cataractogenic Potential of Quetiapine Fumarate (SEROQUEL®) and Risperidone (RISPERDAL®) in the Long-Term Treatment of Patients with Schizophrenia or Schizoaffective Disorder. AstraZeneca. A Multi-Center, Phase III, Randomized, Double-Blind, Clinical Trial to Compare the Safety and Efficacy of Study Compound Gel vs. Clindamycin Phosphate 1.2% Gel in the Treatment of Acne Vulgaris. A Comparison of Zolpidem Tartra Extended-Release Vs. Placebo in the Treatment of Insomnia Associated With Newly Diagnosed Major Depressive Disorder Or Untreated MDD Relapse, When Used Concomitantly With Escitalopram. A Comparison Of Zolpidem Tartrate Extended-Release Vs. Placebo In The Treatment Of Insomnia Associated With Generalized Anxiety Disorder (GAD) When Used Concomitantly With Escitalopram. Olanzapine versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated With Bipolar I Disorder. Efficacy and Safety of Eplivanserin 5mg/day on Sleep Maintenance Insomnia: A 12 week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. A Multicenter, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase III Study of Efficacy and Safety of Quetiapine Fumarate and lithium as Monotherapy in 28 to 104 weeks Maintenance Treatment of Bipolar I Disorder in Adult Patients. A Randomized, Double-blind, Active and Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate The Efficacy And Safety of Extended-Release Paliperidone As Maintenance Treatment After An Acute Manic Or Mixed Episode Associated With Bipolar 1 Disorder. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate The Efficacy, Safety and Tolerability of Licarbazepine 750-2000 mg/d As Adjunctive Therapy To An Atypical Antipsychotic in the Treatment of Manic Episodes of BPD I Over 6 weeks. A Multicenter, Randomized, 24-52 week, Double-blind, Placebo-Controlled Study to Evaluate The Efficacy, Safety, and Tolerability of Saredutant 100 mg Once Daily In The Prevention Of Relapse of Depressive Symptoms In Outpatients With Major Depressive Disorder Who Achieved An Initial Response To 12 Weeks Of Open-Label Treatment With Saredutant 100 mg Once Daily. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active-Controlled Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate (Seroquel) Compared with Placebo in the Treatment of Generalized Anxiety Disorder (Gold study). Multicenter, Double-blind, Randomized, Parallel-group,Placebo-controlled and Active-controlled Phase III Study of the Efficacy and Safety of Quentiapine Funerate Sustained-release (SEROQUEL) as Monotherapy in the treatment of Patients with Major Depressive Disorder A Multicenter, Randomized, Double-Blind, Parallel-Group Fixed-Dose Study of the Effect on Weight of Biferprunox Versus Olanzapine In the Treatment of Outpatients With Schizophrenia. A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR) in Combination with an Antidepressant in the Treatment of Patients with Major Depressive Disorder with Inadequate Response to an Antidepressant A Multicenter, Randomized, Double-Blind, Parallel-Group Fixed-Dose Study of the Effect on Weight of Biferprunox Versus Risperdal In the Treatment of Outpatients With Schizophrenia. A Multi-center, Parallel Group, Fixed Dose, 4-arm, Placebo And Paroxetine Controlled 8-week Efficacy Study of 2 Oral Doses of SR58611A (175 mg or 350 mg, b.i.d.) In Adult Outpatients With Major Depressive Disorder. An Eight-Week, Multicenter, Randomized, Double-blind, Placebo=controlled Study, Evaluating the Efficacy, Safety, and Toleratbility of Two Fixed Doses (100 mf and 30 mg Once Daily) of Saredutant in Patients with Generalized Anxiety Disorder. A Multicenter, Randomized, Double-Blind, Parallel-Group Fixed-Dose Study of the Effect on Weight of Biferprunox Versus Risperdal In the Treatment of Outpatients With Schizophrenia. An Eight-week, Multicenter, Double-Blind, Placebo-and Escitalopram-Controlled Study Evaluating the Efficacy and Tolerability of Two Fixed Does of SSRI49415 (250 mg bid and 100mg bid) In Outpatients with Major Depressive Disorder (Yakima study). An Eight-week, Multicenter, Double-Blind, Placebo- and Paroxetine-controlled Study Evaluating the Efficacy, Safety and Tolerability of Two Fixed Doses of SSR149415 (250 mg bid and 100mg bid) In Outpatients With Generalized Anxiety Disorder. A Multicenter, Double-Blind, Randomized, Parallel-group, Placebo-controlled, Phase III Study of the Efficacy and Safety of Quentapine Funerate (SEROQUEL) Sustained-release as Monotherapy in Adult Patients with Acute Bipolar Mania" A Multicenter, Double-Blind, Randomized, Parallel-group, Placebo-controlled, Phase III Study of the Efficacy and Safety of Quentapine Funerate (SEROQUEL) Sustained-release as Monotherapy in Adult Patients with Acute Bipolar Depression" A Multicenter, Randomized, Double-Blind, Parallel-Group Fixed-Dose Study of the Effect on Weight of Biferprunox Versus Olanzapine In the Treatment of Outpatients With Schizophrenia. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Licarbazepine 750-2000mg/d Combined with Lithium or Valproate in the Treatment of Manic Episodes of Bipolar I Disorder over 6 Weeks and a 52-Week Open Label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder. Efficacy and Safety of 2mg/day of M100907 on Sleep Maintenance Insomnia with a sub-study of the effect of M100907 on stable Type II Diabetes Mellitus: a One Year, multi-center, randomized, double-blind, placebo-controlled study.

Source: http://www.psychiatriccenters.com/extranet/forms/GGM%20CV.pdf